Acceptability of live attenuated influenza vaccine by vaccine providers in Quebec, Canada

Hum Vaccin Immunother. 2015;11(4):956-60. doi: 10.1080/21645515.2015.1009816.

Abstract

A live attenuated influenza vaccine (LAIV) was offered during the 2012-13 influenza season in Quebec, Canada, to children aged between 2 and 17 years with chronic medical conditions. Despite the offer, uptake of the vaccine was low. We assessed the perceptions and opinions about seasonal influenza vaccination and LAIV use among vaccine providers who participated in the 2012-13 campaign. More than 70% of them thought that LAIV was safe and effective and more than 90% considered that the vaccine was well-received by parents and healthcare professionals. According to respondents, the most frequent concerns of parents about LAIV were linked to vaccine efficacy. LAIV is well-accepted by vaccine providers involved in influenza vaccination clinics, but more information about the vaccine and the recommendations for its use are needed to increase vaccine uptake.

Keywords: CLSC; Center local de services communautaires; Flumist; acceptability; attitudes and practices; LAIV; influenza; intranasal; knowledge; live attenuated influenza vaccine; live attenuated influenza vaccine; TIV; local community service center; KAP; trivalent inactivated influenza vaccine; vaccination.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Child
  • Child, Preschool
  • Female
  • Health Personnel / psychology*
  • Humans
  • Influenza Vaccines / therapeutic use*
  • Influenza, Human / prevention & control
  • Male
  • Quebec
  • Vaccines, Attenuated / therapeutic use*

Substances

  • Influenza Vaccines
  • Vaccines, Attenuated